AI, robotics and biotech rounds raise over $1bn in August 2026
Multiple funding events across artificial intelligence, robotics and biotechnology saw significant capital deployment in August 2026, highlighting expanding investor interest in specialised platforms and models.
Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here.
Artificial Intelligence
Accel announced the creation of four new funds totalling $3.5 billion to back early‑stage AI startups globally, allocating $1.35 billion to a global expansion vehicle, $800 million each for dedicated US and Europe/Israel funds, and $550 million for an India‑focused fund, with the capital intended for larger early‑stage rounds and rapid follow‑on investments [2].
Finland‑based STRGY AI secured a $1.2 million angel round backed by Innovestor’s Angel CoFund and Business Finland, aiming to deploy its AI‑driven strategic planning tool across mid‑size and large European enterprises to systematised corporate decision‑making [3].
Former OpenAI chief product officer Kevin Weil is reportedly seeking to raise $150 million at a valuation of at least $750 million for a new AI‑science venture focused on gathering scientific data for model training, though the round remains in discussion and details may change [4].
Robotics
Alloy Robotics announced an $8 million seed round that values the Sydney‑origin company at $80 million, with Square Peg leading the investment and participation from existing backers Blackbird, Airtree and Skip Capital, alongside engineers from OpenAI, Anthropic and other leading AI firms; the funds will support engineering hires, US expansion and further development of its AI‑agent platform for robot‑fleet failure analysis [1].
Genetic Engineering
Aureka Biotechnologies closed a $100 million Series B to train next‑generation biological foundation models and upgrade its Lab‑in‑the‑Loop platform; Granite Asia funded the first tranche, a strategic investor led the second, with HighLight Capital, MPCi and NRL Capital also participating, and the capital will be used for large‑scale model training, de novo molecular design and integrated high‑throughput screening [5][6].
Vaderis Therapeutics raised $152 million in a Series B to advance its AKT inhibitor engasertib through Phase 3 trials for hereditary hemorrhagic telangiectasia, with investors including Life Sciences at Goldman Sachs Alternatives, TCGX, Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, Medicxi and Droia, providing the cash needed for late‑stage clinical development [9].
Epicrispr Biotechnologies secured a $90 million oversubscribed Series C co‑led by Octagon Capital and Janus Henderson Investors, with participation from Fidelity, Cormorant, Duquesne Family Office, Sanofi Ventures, abrdn, Angelini Ventures, Readout Capital and existing backers; proceeds will fund pivotal studies of its epigenetic therapy EPI‑321 for facioscapulohumeral muscular dystrophy, expand the Gene Expression Modulation System platform and scale AAV manufacturing [7][8].
Mironid raised $46 million in a Series B backed by the Scottish National Investment Bank, Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde, to progress its first‑in‑class LoAc small‑molecule cAMP modulator for autosomal dominant polycystic kidney disease through clinical development, aiming to address a major unmet need in hereditary kidney disorders [10].